Ginkgo Bioworks announced on August 20, 2025, that its Datapoints offering has entered into a strategic partnership with Inductive Bio and Tangible Scientific. The collaboration aims to make AI-driven lab-in-the-loop drug discovery broadly accessible across the biopharma industry.
This partnership connects three core capabilities: Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design platform, and Tangible Scientific's API-enabled compound management platform. The integrated service seeks to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream.
The collaboration is designed to reduce the time and uncertainty in early-stage drug development by enabling fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs. It supports the FDA's push for faster, more efficient development timelines and greater use of AI tools.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.